The global erectile dysfunction drugs market is set to decline in the coming few years. The report on the global market for erectile dysfunction drugs market delivers an in-depth analysis of the trends responsible for the decline of this market. Additionally, the report provides statistical support to elaborate on the market’s decline.

The global erectile dysfunction drugs market report provides a 360-degree view of the treatments available in the market for erectile dysfunction (ED). These are localized therapy, vacuum constriction devices, PDE 5 inhibitors, testosterone replacement therapy, and alternative medicines. According to brand, the global erectile dysfunction drugs market is divided into Viagra, Cialis, Stendra/Spedra, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva.

The global erectile dysfunction drugs market research report also evaluates pipeline drugs such as Vitaros, Uprima, and others. Geography-wise, the global erectile dysfunction drugs market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Furthermore, the report also provides strategic recommendations such as cost containment measures, novel drug formulations owing to patent expirations of well-known ED drugs, and M&A tactics to strengthen market presence.

Overview of the global erectile dysfunction drugs market

Factors such as the growing elderly population, increasing awareness and patient education, elevated inclination towards a sedentary lifestyle, and growing incidence of several genitourinary diseases are expected to drive the growth of the global erectile dysfunction drugs market. Nevertheless, factors such as growing threat from counterfeit drugs, prevalence of STDs in ED drug users, and diminishing insurance coverage for ED treatment will greatly hamper the growth of the market.

The global erectile dysfunction drugs market will decelerate at a CAGR of 4.5% during the forecast period of 2013 to 2019. In 2012, the global erectile dysfunction drugs market stood at US$4.3 billion and is expected to reach a market value of US$3.4 billion by end of 2019. The North American erectile dysfunction drugs market held substantial market revenue of US$2,098.4 million in 2012.

The top three erectile dysfunction drugs in the market are Cialis (tadalafil), Staxyn/Levitra (vardenafil), and Viagra (sildenafil citrate). In 2013, Viagra held the largest market share of 45% in the global erectile dysfunction drugs market. The patent expiration of Viagra, especially outside the U.S., in 2013, along with the loss of patent and marketing exclusivity of the drug Levitra from Bayer AG and Cialis from Eli Lilly in Europe and other countries will result in the market’s steady decline.

Nevertheless, the extended patent exclusivity of Viagra till 2020 is anticipated to allow this brand to hold a major market revenue share in the U.S. The market for Cialis is also predicted to demonstrate a decline in revenue during the forecasting horizon. In 2012, Cialis was the second largest drug segment in the global ED drugs market, with revenue of US$1,926.8 million. However, the market for this drug will decline at a 12.6% CAGR during the forecast period.

Companies mentioned in the research report
Players in the market will tap on the opportunity of novel molecule combinations and innovative drug delivery techniques. The most established companies in the global erectile dysfunction drugs market are Bayer AG, Apricus Biosciences, Dong-A Pharmaceutical, Meda Pharmaceuticals, Eli Lilly And Company, Pfizer, Vivus, and S.K. Chemicals.

Major geographies analyzed under this research report are:

• Europe
• North America
• Asia-Pacific
• Rest of the World

This report gives you access to decisive data such as:

• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for the coming years